Last Updated: November 16, 2026

Expiring Drug Patents Cheat Sheet
We analyse the patents covering drugs in 134 countries and quickly give you the likely loss-of-exclusivity/generic entry date

➤ Get the Full List

Turkey: These 4 Drugs Face Patent Expirations and Generic Entry From 2026 - 2027

The content of this page is licensed under a Creative Commons Attribution 4.0 International License. Creative Commons License

Preferred citation:
Friedman, Yali, "Turkey: These 4 Drugs Face Patent Expirations and Generic Entry From 2026 - 2027" DrugPatentWatch.com thinkBiotech, 2026 www.drugpatentwatch.com/p/expiring-drug-patents-generic-entry/.
Media collateral
These estimated drug patent expiration dates and generic entry opportunity dates are calculated from analysis of known patents covering drugs. Many factors can influence early or late generic entry. This information is provided as a rough estimate of generic entry potential and should not be used as an independent source. The methodology is described in this blog post.
When can SEYSARA (sarecycline hydrochloride) generic drug versions launch in Turkey?

Generic name: sarecycline hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 21, 2026
Generic Entry Controlled by: Turkey Patent 201,818,983

SEYSARA is a drug marketed by Almirall. There are four patents protecting this drug.

See drug price trends for SEYSARA.

The generic ingredient in SEYSARA is sarecycline hydrochloride. Additional details are available on the sarecycline hydrochloride profile page.

When can JAKAFI (ruxolitinib phosphate) generic drug versions launch in Turkey?

Generic name: ruxolitinib phosphate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: June 13, 2027
Generic Entry Controlled by: Turkey Patent 201,903,488

JAKAFI is a drug marketed by Incyte Corp. There are nineteen patents protecting this drug and one Paragraph IV challenge. There has been litigation on patents covering JAKAFI

See drug price trends for JAKAFI.

The generic ingredient in JAKAFI is ruxolitinib phosphate. Additional details are available on the ruxolitinib phosphate profile page.

When can EPIDUO (adapalene; benzoyl peroxide) generic drug versions launch in Turkey?

Generic name: adapalene; benzoyl peroxide
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: July 12, 2027
Generic Entry Controlled by: Turkey Patent 201,819,658

Drug Price Trends for EPIDUO
EPIDUO is a drug marketed by Galderma Labs Lp and Galderma LabsThere are three patents protecting this drug and two Paragraph IV challenges. There has been litigation on patents covering EPIDUO

See drug price trends for EPIDUO.

The generic ingredient in EPIDUO is adapalene; benzoyl peroxide. Additional details are available on the adapalene; benzoyl peroxide profile page.

When can EPIDUO FORTE (adapalene; benzoyl peroxide) generic drug versions launch in Turkey?

Generic name: adapalene; benzoyl peroxide
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: July 12, 2027
Generic Entry Controlled by: Turkey Patent 201,819,658

Drug Price Trends for EPIDUO FORTE
EPIDUO FORTE is a drug marketed by Galderma Labs. There has been litigation on patents covering EPIDUO FORTE

See drug price trends for EPIDUO FORTE.

The generic ingredient in EPIDUO FORTE is adapalene; benzoyl peroxide. Additional details are available on the adapalene; benzoyl peroxide profile page.

Turkey Branded and Generic Drug Market Assessment: Regulation, Patent Risk, Pricing and Commercial Opportunities

Last updated: October 13, 2026

Turkey is a large, price-regulated pharmaceutical market with universal public reimbursement, strong generic penetration, and growing local manufacturing capacity. Market access depends on Turkish Medicines and Medical Devices Agency approval, Social Security Institution reimbursement, reference pricing, localization policy, and supply continuity. The main opportunities are generic substitution, biosimilars, contract manufacturing, technology transfer, hospital products, and locally produced active pharmaceutical ingredients. The main risks are currency volatility, delayed price adjustments, reimbursement restrictions, compulsory licensing exposure, import disruption, and limited commercial value from patent protection without reimbursement access.

How large is Turkey's branded and generic drug market?

Turkey is one of the largest pharmaceutical markets in the Middle East and Europe by population and prescription volume. The market is dominated by reimbursed prescription medicines, with the Social Security Institution, or SGK, acting as the principal public payer. Private out-of-pocket and private-insurance sales are smaller than public reimbursement but remain relevant in consumer health, premium products, and products outside reimbursement lists.

Market characteristic Turkey assessment
Population base More than 85 million people
Primary regulator Turkish Medicines and Medical Devices Agency, TITCK
Main public payer Social Security Institution, SGK
Core reimbursement framework Health Implementation Communiqué, known as SUT
Pricing model External reference pricing with periodic Turkish lira conversion
Generic market Large and structurally important
Branded market Strong in innovative, specialty, hospital and patented products
Retail channel Community pharmacies remain central
Hospital channel Public tenders and centralized procurement are material
Local production Significant, supported by industrial and localization policies
Currency exposure High, particularly for imported products and APIs

Turkey's pharmaceutical sales have expanded sharply in Turkish lira terms because of inflation and repeated price revisions. Unit growth is more moderate. Nominal revenue growth therefore overstates underlying volume growth and does not translate directly into hard-currency revenue.

Generic medicines are central to the market because SGK reimbursement frequently applies price controls, reference pricing, and patient co-payment rules that favor lower-priced alternatives. Innovative products retain commercial value where they offer clinical differentiation, qualify for premium reimbursement treatment, or address oncology, rare disease, immunology, diabetes, and other high-need indications.

What is the regulatory status of medicines in Turkey?

TITCK regulates human medicinal products, marketing authorization, pharmacovigilance, manufacturing, distribution, inspections, and certain clinical-trial functions. The principal framework is Turkey's Regulation on the Licensing of Human Medicinal Products, supported by Good Manufacturing Practice, Good Distribution Practice, pharmacovigilance, clinical-trial, and promotional rules.[1]

A product normally requires a Turkish marketing authorization before commercial sale. Applications include full dossiers for new active substances, abridged applications for generics, hybrid applications for certain reformulated or partially supported products, and biological applications under the applicable national framework.

What is the Turkish approval pathway for branded medicines?

Innovative products generally require quality, nonclinical, and clinical documentation. Turkey recognizes data and regulatory standards influenced by European Union practice, but the application is submitted to TITCK under Turkish procedures. Local administrative requirements, Turkish-language labeling, pharmacovigilance arrangements, and manufacturing-site compliance remain important.

Key regulatory requirements include:

  • Turkish marketing authorization.
  • Approved Turkish product information and packaging.
  • Qualified local representative or authorization holder arrangements.
  • Pharmacovigilance system and safety reporting.
  • GMP compliance for relevant manufacturing sites.
  • Serialization and traceability under the Turkish pharmaceutical tracking system.
  • Pricing approval before commercial launch.
  • SGK reimbursement listing where public reimbursement is required.

How are generic drugs approved in Turkey?

Generic applicants generally rely on the reference product's established safety and efficacy record and submit pharmaceutical quality data plus bioequivalence evidence where required. The Turkish framework includes a Bolar-type exemption that permits activities connected with obtaining marketing authorization before patent expiry. This reduces the need for generic manufacturers to wait until patent expiration to complete development, testing, and regulatory filings.[2]

A generic marketing authorization does not guarantee commercial launch. The applicant still faces:

  1. Patent litigation risk.
  2. Reimbursement-listing requirements.
  3. Price approval.
  4. Manufacturing and supply obligations.
  5. Pharmacy substitution and discount dynamics.
  6. Potential launch injunctions or other court remedies.

What are Turkey's pricing and reimbursement rules?

Turkey uses an external reference-pricing system. The price of a medicine is generally linked to reference countries and converted into Turkish lira using an official or administratively determined euro rate. The applied rate has often lagged the market exchange rate, creating pressure on imported products, foreign currency costs, and local manufacturers dependent on imported active pharmaceutical ingredients.[3]

SGK reimbursement is governed mainly by the SUT. Reimbursement can depend on indication, treatment line, specialist prescription, hospital use, prior authorization, clinical criteria, and product listing.

Why is reimbursement more important than marketing authorization?

A product can receive TITCK approval but have limited market access if it is not included in SGK reimbursement schedules. Commercial success therefore requires coordinated execution across:

  • Regulatory approval.
  • Price approval.
  • Reimbursement application.
  • Physician and hospital access.
  • Pharmacy distribution.
  • Supply continuity.
  • Local manufacturing or procurement commitments where applicable.

Innovative products can face reimbursement delays or restrictive clinical criteria. Generic products usually obtain faster volume adoption if they achieve an acceptable price position and are included in the relevant reimbursement framework.

What pricing challenges affect branded and generic drugs?

The main challenges are:

  • Exchange-rate mismatch between official pricing and actual import costs.
  • Inflation-driven operating-cost increases.
  • Delayed price updates.
  • Mandatory discounts and reimbursement deductions.
  • Low-margin tender pricing.
  • Increased risk of product withdrawal where supply becomes uneconomic.
  • Working-capital pressure caused by payment timing.

For multinational companies, the commercial problem is often measured in euros or dollars, while revenue is collected in Turkish lira. For domestic manufacturers, imported API and packaging costs create similar currency exposure.

How many patents protect medicines in Turkey?

Turkey does not provide a US-style Orange Book system that consolidates all patents associated with an approved medicine. Patent information is administered through the Turkish Patent and Trademark Office and national patent records. Patent holders must evaluate product, formulation, process, manufacturing, dosage, and method-of-use claims separately.

Patent category Commercial relevance in Turkey
Composition-of-matter patent Usually the strongest protection for a new active ingredient
Salt, polymorph or crystalline-form patent Can delay some generic approaches but is vulnerable to validity challenges
Formulation patent Relevant where the dosage form has technical differentiation
Process patent Important for manufacturing routes and API sourcing
Method-of-use patent May protect a specific indication or patient population
Device or delivery patent Relevant to injectors, inhalers, transdermal systems and combination products
Supplementary protection Turkey does not provide an EU-style SPC regime with equivalent breadth

Turkey is a member of the Paris Convention, the Patent Cooperation Treaty, and the World Trade Organization TRIPS Agreement. Patent terms generally run for 20 years from the filing date under the Industrial Property Code No. 6769.[2]

What data exclusivity applies to pharmaceutical products?

Turkey provides pharmaceutical regulatory data protection in defined circumstances, generally for six years from the relevant first authorization date in a customs-union country, subject to the applicable Turkish rules and timing conditions.[4] Data exclusivity should be analyzed separately from patent protection. A generic may face either:

  • Patent-based delay;
  • Data-exclusivity restrictions;
  • Both protections;
  • Or neither, if the relevant periods have expired.

The practical value of data exclusivity is greatest where patent protection is weak, expired, or absent. Its value is lower where a strong composition patent remains enforceable.

What is the Orange Book status of medicines in Turkey?

Turkey has no direct equivalent to the US FDA Orange Book. TITCK approval records and SGK reimbursement documents do not operate as a consolidated patent-linkage register. Patent holders cannot rely on automatic administrative listing to prevent a generic application or launch.

This creates a litigation-centered patent environment. Innovators typically need to:

  1. Monitor Turkish patent records.
  2. Identify expected generic entrants.
  3. Assess validity and infringement claim by claim.
  4. File Turkish civil patent proceedings where appropriate.
  5. Seek interim measures when legally available.
  6. Coordinate Turkish litigation with global settlement and launch strategy.

How do Paragraph IV challenges work in Turkey?

Turkey does not use the US Hatch-Waxman Paragraph IV certification system. Generic companies do not file a US-style certification asserting that a listed patent is invalid or not infringed. Instead, patent disputes can arise through:

  • Patent infringement litigation by the originator.
  • Invalidity actions by the generic applicant.
  • Declaratory or non-infringement proceedings where available.
  • Customs actions involving allegedly infringing goods.
  • Interim injunction applications.
  • Administrative and commercial disputes involving market authorization or launch activity.

The absence of formal Paragraph IV litigation does not eliminate early patent challenges. It changes the timing, evidence, and procedural strategy. Generic manufacturers can conduct development and regulatory work under the Bolar exemption, then decide whether to launch after patent analysis or litigation.

What formulation and method-of-use patents matter most?

Formulation patents are increasingly relevant as composition patents expire. The strongest formulation portfolios usually address a measurable technical problem, such as stability, controlled release, bioavailability, injection compatibility, particle size, or device performance.

Common patent categories include:

  • Extended-release tablets and capsules.
  • Long-acting injectable formulations.
  • Ready-to-use biologic presentations.
  • Fixed-dose combinations.
  • Pediatric formulations.
  • Abuse-deterrent dosage forms.
  • Inhaled formulations and device combinations.
  • Refrigeration and stability improvements.
  • Specific dosing regimens or treatment populations.

Method-of-use patents may have commercial value where SGK reimbursement is indication-specific. Enforcement is more complex than composition-patent enforcement because the product itself may have non-infringing uses. Generic labeling, physician prescribing, pharmacy substitution, and reimbursement rules become important evidence.

What is the biosimilar risk in Turkey?

Biosimilars represent a medium- to long-term competitive risk for biological products, especially oncology, rheumatology, endocrinology, and supportive-care medicines. Turkey has regulatory pathways for biological and biosimilar products, but market access depends on product-specific evidence, interchangeability treatment, physician confidence, procurement, reimbursement and price differentials.

Why are biosimilars commercially attractive?

Biosimilars can benefit from:

  • Large public-payer demand.
  • High cost of originator biologics.
  • Hospital procurement incentives.
  • Local manufacturing and technology-transfer policy.
  • Growing domestic biologics capability.
  • Expiring biologic composition and formulation protection.

The principal barriers are complex manufacturing, analytical comparability, clinical requirements, cold-chain logistics, immunogenicity monitoring, and physician adoption. Biosimilar entry is more capital-intensive than small-molecule generic entry and can produce fewer competitors.

Which companies are competing in Turkey?

The market includes four main groups:

Competitor group Typical strengths
Multinational originators Innovative products, clinical evidence, global manufacturing and specialty portfolios
Large Turkish manufacturers Broad generic portfolios, local production, distribution and reimbursement experience
Regional manufacturers Cost-efficient production and selected branded-generics portfolios
Contract manufacturers Technology transfer, local supply and tender participation

Major Turkish companies have historically included Abdi Ibrahim, Nobel İlaç, Bilim İlaç, Deva Holding, Santa Farma, İlaç, and Sanofi's Turkey operations, alongside multinational companies such as Pfizer, Novartis, Roche, AstraZeneca, Bayer, Merck, GSK, Johnson & Johnson, and others. Competitive positions vary by therapeutic area and product.

Companies with local manufacturing, strong pharmacy distribution, and reliable SGK execution generally have an advantage over import-only suppliers. Foreign companies can reduce exposure through licensing, contract manufacturing, local packaging, Turkish joint ventures, or technology-transfer arrangements.

What licensing and manufacturing opportunities exist?

Turkey offers opportunities for:

  • Local manufacture of mature small-molecule products.
  • Biosimilar development and fill-finish.
  • API and intermediate production.
  • Contract manufacturing for multinational companies.
  • Co-marketing and licensing of branded generics.
  • Technology transfer tied to public procurement.
  • Export manufacturing to Europe, the Middle East, North Africa and Central Asia.
  • Hospital products and injectable medicines.
  • Supply of shortage-prone products.

Licensing agreements should address Turkish pricing, reimbursement, minimum supply commitments, pharmacovigilance, trademark ownership, patent responsibility, product liability, technology transfer, and currency adjustment. A nominal royalty rate can become commercially unattractive if Turkish prices do not track costs.

Manufacturing localization can improve supply resilience and public-sector access but requires capital, GMP compliance, validation, qualified personnel, environmental approvals and reliable API sourcing. Local production is not a complete solution to currency risk because many APIs, excipients, packaging materials and manufacturing equipment remain imported.

What litigation and settlement risks affect market entry?

Patent litigation is concentrated in civil courts and may involve validity, infringement, interim measures, customs, evidence preservation and technical expert analysis. Litigation timelines can be commercially important because a generic may obtain regulatory approval before resolving the patent position.

Settlement agreements require careful review for:

  • Launch dates.
  • Authorized-generic arrangements.
  • Supply or licensing terms.
  • Patent validity admissions.
  • Restrictions on affiliates and future products.
  • Competition-law risk.
  • Confidentiality and disclosure.
  • Treatment of new formulations and indications.

A settlement that fixes a launch date below the remaining patent term may still face regulatory and reimbursement delays. Conversely, a favorable court outcome may have limited value if the product cannot obtain an economic SGK price.

When does a branded medicine lose exclusivity in Turkey?

Loss of exclusivity is not determined by one date. The relevant timeline may include:

Event Commercial effect
Patent filing date Starts the ordinary 20-year patent term calculation
Marketing authorization Enables legal sale after pricing and other requirements
Data-exclusivity start May restrict reliance on originator data for the applicable period
Composition-patent expiry Opens the principal generic-entry opportunity
Formulation or process-patent expiry May leave residual protection
Method-of-use expiry May affect indication-specific entry
Reimbursement listing of generic Enables meaningful public-payer access
First generic launch Can trigger rapid price erosion

Companies should model exclusivity at the product-and-claim level, not solely by the originator approval date.

What generic launch scenarios exist in Turkey?

Early launch after patent clearance

A generic launches after confirming that relevant patents are expired, invalid, unenforceable or not infringed. This is the lowest litigation-risk scenario.

At-risk launch

The generic launches while patent litigation remains pending. The company accepts potential damages, injunctions and supply disruption in exchange for first-mover volume.

Settlement-based launch

The originator and generic company agree on a future entry date, license, supply arrangement or other commercial structure. Competition-law review is essential.

Hospital-first launch

The product enters through tenders or hospital channels before achieving broad retail penetration. This is common for injectables and institutional medicines.

Localized manufacturing launch

The company combines Turkish production or packaging with reimbursement and public-procurement advantages. This can improve supply security but increases fixed costs.

What are the main regulatory opportunities and challenges?

Opportunity Challenge
Large population and public reimbursement Price compression
Generic substitution Currency and inflation exposure
Biosimilar expansion Complex evidence and manufacturing
Local production incentives High capital and compliance costs
Export platform potential EU and destination-market requirements
Hospital procurement Tender price pressure
Technology-transfer deals Execution and IP-control risk
Specialty and orphan medicines Reimbursement and budget constraints

What is the investment outlook for Turkey's drug market?

Turkey is attractive for companies with a long-term operating model, local regulatory capability, and tolerance for currency volatility. The strongest opportunities are likely to come from products with one or more of the following characteristics:

  • High unmet clinical need.
  • Limited local competition.
  • Public-health importance.
  • Supply shortages.
  • Local manufacturing potential.
  • Biosimilar or complex-generic barriers.
  • Export potential.
  • Clear reimbursement value.

Pure import-and-distribute models face greater pressure when official prices fail to reflect landed costs. Innovative products face reimbursement and affordability risk. Generic companies face price erosion but can offset it through portfolio breadth, manufacturing efficiency, tenders and export sales.

Key Takeaways

  • Turkey is a large, reimbursement-driven pharmaceutical market with strong generic penetration.
  • TITCK approval is necessary but does not ensure SGK reimbursement or commercial success.
  • Turkey has no US-style Orange Book or Paragraph IV system.
  • Patent protection generally lasts 20 years from filing, with separate analysis required for formulation, process and method-of-use claims.
  • Regulatory data exclusivity can provide six years of protection in applicable cases.
  • External reference pricing and exchange-rate controls create persistent margin pressure.
  • Local production, biosimilars, complex generics, contract manufacturing and technology transfer offer the strongest structural opportunities.
  • Imported products and API-dependent manufacturers face high currency and supply risks.
  • Patent strategy must be integrated with pricing, reimbursement, procurement and manufacturing decisions.

FAQs on Turkey's Pharmaceutical Market

Is Turkey favorable for generic drug launches?

Yes, particularly for products with expired composition patents, established reimbursement pathways, competitive manufacturing costs and broad pharmacy distribution. Price controls can materially limit margin.

Does Turkey have patent linkage between TITCK approval and patent status?

Turkey does not operate a comprehensive US-style patent-linkage or Orange Book system. Patent enforcement is primarily pursued through civil litigation and related court remedies.

Can a generic company perform clinical and bioequivalence work before patent expiry?

Yes. Turkey has a Bolar-type exemption for activities reasonably connected with obtaining regulatory approval, subject to the applicable statutory conditions.

Are biosimilars automatically interchangeable with originator biologics in Turkey?

No. Interchangeability and substitution depend on the applicable regulatory, reimbursement, physician and procurement framework. Product-specific assessment is required.

What is the biggest commercial risk for multinational pharmaceutical companies in Turkey?

The largest combined risk is the gap between Turkish-lira revenues and foreign-currency costs, intensified by reference pricing, delayed price adjustments, reimbursement restrictions and supply obligations.

References

  1. Turkish Medicines and Medical Devices Agency. (2017, as amended). Regulation on the licensing of human medicinal products. Ankara, Türkiye.

  2. Republic of Türkiye. (2017, as amended). Industrial Property Code No. 6769. Official Gazette of the Republic of Türkiye.

  3. Republic of Türkiye, Ministry of Health. (2023, as amended). Regulation on the pricing of medicinal products for human use. Official Gazette of the Republic of Türkiye.

  4. Republic of Türkiye. (2001, as amended). Communiqué on the protection of undisclosed information and data submitted for the registration of pharmaceutical products. Official Gazette of the Republic of Türkiye.

  5. Social Security Institution. (2024, as amended). Health Implementation Communiqué. Ankara, Türkiye.

  6. Turkish Medicines and Medical Devices Agency. (2024). Guidelines and regulatory documents for medicinal products, biological products and pharmacovigilance. Ankara, Türkiye.

  7. Organisation for Economic Co-operation and Development. (2023). Health at a glance 2023: OECD indicators. OECD Publishing.

More… ↓

⤷  Start Trial

DrugPatentWatch cited by CNN, NEJM, Nature Journals, and more …

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.